Biotech stocks went on a seesaw ride along with the broader markets in the week ended June 26. Yet there were some encouraging developments on the COVID-19 vaccine development front. Vaccine companies are going all out, forging alliances and adding personnel that could help them be successful in their quest.Translate Bio Inc (NASDAQ: TBIO) rallied strongly earlier in the week on the back of news concerning an expansion of its vaccine development partnership with Sanofi SA (NASDAQ: SNY) but eventually gave back some of the gains following a secondary offering. Vaxart Inc (NASDAQ: VXRT), another COVID-19 vaccine play, rallied during the week.View more earnings on IBBThe FDA review machinery worked overtime, ruling on a host of investigational therapies. Three biopharma companies went public this week, raising a combined $485 million in gross proceeds.The following are key catalysts in the unfolding week:Conferences * Cantor Fitzgerald's Virtual Symposium: "Winning Ways to Treat Infections and COVID-19: Tuesday, June 30Clinical Readouts/Presentations Q2 Releases * Intra-Cellular Therapies Inc (NASDAQ: ITCI) is scheduled to release top-line results from Phase 1/2 clinical trial of ITI-214, its phosphodiesterase 1 inhibitor, in patients with chronic systolic heart failure. * Obseva SA (NASDAQ: OBSV) will release Phase 3 PRIMROSE 1, 6-month primary endpoint results and PRIMROSE 2 twelve-month data for Linzagolix in uterine fibroids. * Novavax, Inc. (NASDAQ: NVAX) is scheduled to release top-line data from Matrix M vaccine adjuvant, which is a key component of Serum Institute of India's malaria vaccine candidate. * Revance Therapeutics Inc (NASDAQ: RVNC) is due to release Phase 2 top-line data for DAXI in forehead lines and crow's feet. * Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE) is expected to release topline data from the pivotal CONNECT-FX trial that is evaluating Zygel in Fragile X syndrome. * Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) will release interim results from Phase 2 studies of ALXN2040 in C3 Glomerulopathy. * Iterum Therapeutics PLC (NASDAQ: ITRM) is due to release Phase 3 topline results from sulopenem clinical trials in uncomplicated urinary tract infections.See also: Novavax Gains Over 50% In June: What's Driving The Rally? First-Half Releases * Cerecor Inc (NASDAQ: CERC) is due to release initial data readout from the Phase 1 trial of CERC-802 in healthy volunteers. * Novartis AG (NYSE: NVS) will release Phase 2 data for LJN452 in non-alcoholic steatohepatitis. * Regenxbio Inc (NASDAQ: RGNX) is due to give a program update from the Phase 1/2 trial of RGX-501 for the treatment of Homozygous Familial Hypercholesterolemia. * BioNTech SE – ADR (NASDAQ: BNTX) will release Phase 1 data for BNT111 in advanced melanoma.June Releases * Inovio Pharmaceuticals Inc (NASDAQ: INO) will release interim Phase 1 data for its coronavirus vaccine candidate INO-4800.Earnings * Avid Bioservices Inc (NASDAQ: CDMO) (Tuesday after the close) IPO Quiet Period Expiration * Pliant Therapeutics Inc (NASDAQ: PLRX) * Legend Biotech Corp (NASDAQ: LEGN) * Applied Molecular Transport Inc. (NASDAQ: AMTI) * CALLIDITAS THER/S ADR (NASDAQ: CALT) * Related Link: The Daily Biotech Pulse: Chiasma, Heron Await FDA Decisions, DBV Restructures, 3 Biopharmas Make Wall Street Debuts See more from Benzinga * The Daily Biotech Pulse: Merck's Wonder Cancer Drug Snags Another Approval, Decision Day For Zogenix, UniQure Out-Licenses Gene Therapy * The Daily Biotech Pulse: MediciNova On Track For European Patent Win, Partial Clinical Hold Lifted For Innate Pharma, Tela Bio Details Coronavirus Impact(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
